Skip to main content

CORRECTION article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1527232

Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib

Provisionally accepted
Chenghao Fu Chenghao Fu 1*昊楠 杜 昊楠 杜 2Qiang Wang Qiang Wang 3Weiyou Zhu Weiyou Zhu 2Guangli Bian Guangli Bian 4Zhujuan Zhong Zhujuan Zhong 5Yuheng Wang Yuheng Wang 1Lei Cao Lei Cao 6
  • 1 Department of Thoracic Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
  • 2 Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
  • 3 Department of Thoracic Surgery, Taizhou Fourth People's Hospital, Taizhou, Jiangsu Province, China
  • 4 Department of Radiology, The First People’s Hospital of Suqian, , Jiangsu, China, Suqian, China
  • 5 Department of Pathology, The First People’s Hospital of Suqian, Suqian, Jiangsu Province, China
  • 6 Department of Oncology, Suqian First People's Hospital, Suqian, Jiangsu Province, China

This article is a correction to:

  1. A Golden Tail of Immunotherapy: Significant Tail Effect in a Chemotherapy-Resistant Advanced Pulmonary Sarcomatoid Carcinoma Patient Treated by Sintilimab Combined with Anlotinib

    1. Read original article

The final, formatted version of the article will be published soon.

    Corrigendum on:Not yet on PUBMED. doi:10.3389/fimmu.2024.1452195 Incorrect Affiliation In the published article, there was an error in affiliations [4,5,6]. Instead of “[The First People’s Hospital of Suqian]”, it should be “[The Affiliated Suqian First People's Hospital of Nanjing Medical University]”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: tail effect, Immunotherapy, cancer therapy, PSC, ICI, Sintilimab

    Received: 13 Nov 2024; Accepted: 14 Nov 2024.

    Copyright: © 2024 Fu, 杜, Wang, Zhu, Bian, Zhong, Wang and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chenghao Fu, Department of Thoracic Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.